Program
bulumtatug fuvedotin
Also written as “9MW2821”, “CVL006 in combination with 9MW2821” and “9MW2821+other anticancer therapy”.
Its studies are mostly in Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell · Uterine Cervical Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience | 1212 open or running | phase 3since Dec 12, 2023 | Jan 19, 2022 | Dec 31, 2026phase 2 · NCT06079112 |
| Convalife (Shanghai) | 11 open or running | phase 2since May 6, 2026 | May 6, 2026 | Apr 30, 2029phase 2 · NCT07615660 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 19, 2022First study: phase 2 study in Solid TumorsNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT05216965 · 208 planned · China
- Feb 22, 2023Phase 1 study in Advanced Malignant Solid TumorsMabwell (Shanghai) Bioscience · NCT05773937 · 40 planned · China
- Sep 25, 2023Phase 2 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06079112 · 100 planned · China
- Dec 12, 2023Phase 3 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06196736 · 432 planned · China
- Jul 1, 2024Phase 2 study in Triple Negative Breast NeoplasmsMabwell (Shanghai) Bioscience · NCT06492005 · 160 planned · China
- Sep 9, 2024Phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326 · 460 planned · China
- Nov 14, 2024Phase 3 study in Uterine Cervical NeoplasmsMabwell (Shanghai) Bioscience · NCT06692166 · 420 planned · China
- Mar 20, 2025Phase 1 study in Triple Negative Breast NeoplasmsMabwell (Shanghai) Bioscience · NCT06908928 · 52 planned · United States
- Apr 8, 20252 phase 2 studiesMabwell (Shanghai) Bioscience · NCT06926998, NCT06947226
- Dec 18, 2025Phase 2 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT07314723 · 90 planned · China
- Apr 22, 2026Phase 3 study in Triple Negative Breast NeoplasmsMabwell (Shanghai) Bioscience · NCT07556848 · 356 planned · China
- May 6, 2026Convalife (Shanghai)'s first study: phase 2 study in Advanced Solid TumorNew to Convalife (Shanghai)Convalife (Shanghai) · NCT07615660 · 108 planned
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06079112
- May 2027Primary completion: phase 1 study in Triple Negative Breast NeoplasmsMabwell (Shanghai) Bioscience · NCT06908928
- May 1, 2027Primary completion: phase 2 study in Gynecological MalignanciesMabwell (Shanghai) Bioscience · NCT06926998
- Sep 2027Primary completion: phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326
TargetBeta
“An antibody drug conjugate (ADC) composed of bulumtatug, a humanized monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically ”NCIt, by rule
Other programs on NECTIN4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enfortumab vedotinrule | Astellas Pharma | phase 4 | 20 |
| notiretatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 14 |
| Sutantatug Envedotinrule | CSPC Pharmaceutical Group | phase 3 | 6 |
| zelenectide pevedotinrule | bicycletx-limited | phase 2 | 5 |
| Anti-nectin-4 Antibody-drug Conjugate MK-3120rule | Merck | phase 2 | 5 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-nectin-4 Antibody-drug Conjugate IPH4502rule | innate-pharma | phase 1 | 1 |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | rondo-therapeutics | phase 1 | 1 |
| CT-202rule | context-therapeutics-inc | phase 1 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07615660Advanced Solid Tumor | 2 | Not yet recruiting | Convalife (Shanghai) | Apr 30, 2029 | 108 |
| NCT07556848Triple Negative Breast Neoplasms · China | 3 | Not yet recruiting | Mabwell (Shanghai) Bioscience | Dec 2027 | 356 |
| NCT07314723Carcinoma, Transitional Cell · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Dec 31, 2027 | 90 |
| NCT06947226Solid Tumors · China | 2 | Not yet recruiting | Mabwell (Shanghai) Bioscience | Apr 2026 | 188 |
| NCT06926998Gynecological Malignancies · China | 2 | Not yet recruiting | Mabwell (Shanghai) Bioscience | May 1, 2027 | 260 |
| NCT06908928Triple Negative Breast Neoplasms · United States | 1 | Recruiting | Mabwell (Shanghai) Bioscience | May 2027 | 52 |
| NCT06692166Uterine Cervical Neoplasms · China | 3 | Recruiting | Mabwell (Shanghai) Bioscience | Dec 9, 2027 | 420 |
| NCT06592326Carcinoma, Transitional Cell · China | 3 | Recruiting | Mabwell (Shanghai) Bioscience | Sep 2027 | 460 |
| NCT06492005Triple Negative Breast Neoplasms · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Jul 2026 | 160 |
| NCT06196736Advanced Urothelial Carcinoma · China | 3 | Recruiting | Mabwell (Shanghai) Bioscience | Sep 2026 | 432 |
| NCT06079112Advanced Urothelial Carcinoma · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Dec 31, 2026 | 100 |
| NCT05773937Advanced Malignant Solid Tumors · China | 1 | Recruiting | Mabwell (Shanghai) Bioscience | Dec 31, 2024 | 40 |
| NCT05216965Solid Tumors · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Dec 2025 | 208 |
How it is read
Names in the registry
- “9MW2821”, 10 entries
- “bulumtatug fuvedotin”, 2 entries
- “CVL006 in combination with 9MW2821”, 2 entries
- “9MW2821+other anticancer therapy”, 1 entry
Conditions, from the studies’ own filings
- Triple Negative Breast Neoplasms, 3 studies
- Carcinoma, Transitional Cell, 2 studies
- Uterine Cervical Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.